Hagmann W K, Kissinger A L, Shah S K, Finke P E, Dorn C P, Brause K A, Ashe B M, Weston H, Maycock A L, Knight W B
Department of Medicinal Chemical Research, Merck Research Laboratories, Rahway, New Jersey 07065.
J Med Chem. 1993 Mar 19;36(6):771-7. doi: 10.1021/jm00058a015.
The effect of changing the C-4 substituent of 3,3-diethyl-1-[(benzylamino)carbonyl]-2-azetidinone on inhibition of HLE and in a model of HLE-induced lung damage in hamsters was explored. Substituents at this position do not appear to interact strongly with HLE with the most potent compounds having k(obs)/[I] = 6900 M-1 s-1. However, substituents at this position had a marked effect on in vivo activity. The greatest oral activity in the lung hemorrhage assay was achieved with C-4 aryl carboxylic acid ethers (60-85% inhibition at 30 mg/kg po). Based upon the established mechanism of inhibition by these compounds, the C-4 substituent would be released, and therefore, the pharmacological potential of these C-4 substituents was of considerable concern. Fortunately, compounds containing 4-hydroxybenzoic acid and 4-hydroxyphenylacetic acid ethers at C-4 were among the most active analogs. These phenolic acids are also found as urinary metabolites in healthy humans. Other heteroaryls at C-4 were also orally active in this model despite relatively modest enzyme activity.
研究了改变3,3 - 二乙基 - 1 - [(苄基氨基)羰基]-2 - 氮杂环丁酮的C - 4取代基对人白细胞弹性蛋白酶(HLE)抑制作用以及在HLE诱导的仓鼠肺损伤模型中的影响。该位置的取代基似乎与HLE的相互作用不强,最有效的化合物的k(obs)/[I] = 6900 M-1 s-1。然而,该位置的取代基对体内活性有显著影响。在肺出血试验中,C - 4芳基羧酸醚具有最大的口服活性(口服30 mg/kg时抑制率为60 - 85%)。基于这些化合物既定的抑制机制,C - 4取代基会被释放,因此,这些C - 4取代基的药理潜力备受关注。幸运的是,C - 4位含有4 - 羟基苯甲酸和4 - 羟基苯乙酸醚的化合物是活性最高的类似物之一。这些酚酸在健康人体内也是尿液代谢产物。尽管酶活性相对适中,但C - 4位的其他杂芳基在该模型中也具有口服活性。